While SHP expression was not significantly altered, phosphorylation of SHP at T55 was dramatically decreased in both mild and severe NAFLD patients, suggesting FGF19 signaling is impaired in these patients as previously reported41. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatotic liver disease.